Weixinkang's Potassium Aspartate Injection New Specification Approved and Deemed to Have Passed Consistency Evaluation

Regulation
โดย Jiemian·CN·Read original
Summary · why it matters

Weixinkang's wholly-owned subsidiary Yangpu Jingtai has received the Drug Supplementary Application Approval Notice for Potassium Aspartate Injection issued by the National Medical Products Administration, approving the addition of a new specification of 20 milliliters, containing 3.424 grams of potassium aspartate, and deeming it to have passed the consistency evaluation. The drug is an electrolyte supplement used to treat hypokalemia caused by various reasons. According to data from Menet, in 2025 the drug's terminal sales in domestic urban public hospitals and county-level public hospitals amounted to 412 million yuan, and the company's cumulative research and development investment was approximately 1.2184 million yuan. Weixinkang stated that it has begun pre-launch preparations, but future sales are subject to uncertainties due to factors such as the market environment and bidding processes.

Impact on stocks 1

Others▲ · 1 stocks
Tibet Weixinkang Medicine Co Ltd
603676
▲ PositiveRegulationrelevance

NMPA approved a new 20ml specification of its Potassium Aspartate Injection and deemed it passed consistency evaluation, a regulatory approval that supports future sales.

Off-coverage companies 1

洋浦京泰Private▲ Positive
Regulationrelevance

The wholly-owned subsidiary received the NMPA supplementary application approval for the new specification and consistency evaluation of Potassium Aspartate Injection.

© 2026 MarketDXNews